Slate Path Capital is a financial services firm based in New York City, specializing in portfolio management and investment advice. The firm typically invests in post-IPO equity rounds and Series B funding, focusing on sectors such as therapeutics and materials. Notable investments include Cyclerion Therapeutics, MP Materials, and Tvardi Therapeutics, with significant capital raised in each.
Key partners at Slate Path Capital bring extensive experience from various high-profile financial institutions. The firm's investment philosophy emphasizes strategic growth and long-term value creation. Additionally, Slate Path Capital offers unique value-add services to its portfolio companies, including tailored financial advice and robust portfolio management support.
Portfolio Snapshot
Observed round participation, including acquisitions and grants. Current holdings, investor exits, and write-offs are not established.
